Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Employees

674

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-20	32.28 $	-2.06%	909,394
25-06-18	32.96 $	+1.96%	583,113
25-06-17	32.32 $	-0.45%	784,137
25-06-16	32.47 $	+1.37%	1,197,331

Delayed Quote Nasdaq, June 20, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

32.28USD

Average target price

39.00USD

Spread / Average Target

+20.82%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-20 EDT			5-day change	1st Jan Change
32.28 ^USD	-2.06%		+0.78%	-10.73%

06-16	Deals of the day-Mergers and acquisitions	RE
06-16	Sector Update: Health Care Stocks Retreat Late Afternoon	MT

Capitalization	2.02B 1.75B 1.65B 1.5B 2.78B 175B 3.13B 19.56B 7.48B 80.2B 7.58B 7.42B 295B	P/E ratio 2025 *	-380x	P/E ratio 2026 *	106x
Enterprise value	2.02B 1.75B 1.65B 1.5B 2.78B 175B 3.13B 19.56B 7.48B 80.2B 7.58B 7.42B 295B	EV / Sales 2025 *	3.23x	EV / Sales 2026 *	2.97x
Free-Float	94.99%	Yield 2025 *	-	Yield 2026 *	-

Deals of the day-Mergers and acquisitions	06-16	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	06-16	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	06-16	MT
Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc. - M&A Call	06-16
Top Midday Stories: Equity Markets Rise on Hopes of Containment of Israel-Iran Hostilities; Meta to Introduce Ads on WhatsApp	06-16	MT
Supernus enters depression drug market with up to $795 million Sage deal	06-16	RE
Deals of the day-Mergers and acquisitions	06-16	RE
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	06-16	MT
Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral	06-16	MT
Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio	06-16	RE
Supernus Pharmaceuticals to Acquire Sage for Up to $795 Million in Cash	06-16	MT
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal	06-16	RE
Supernus Pharmaceuticals, Inc. Announces Paragraph IV ANDA Filings for Qelbree®?	05-28	CI

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral	06-16	MT
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57	02-19	MT
Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target	01-06	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	24-03-25	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	24-03-21	MT

Supernus Pharmaceuticals, Inc. Stock

Equities

SUPN

US8684591089

Pharmaceuticals

Valuation: Supernus Pharmaceuticals, Inc.

Chart: Supernus Pharmaceuticals, Inc.

Latest news: Supernus Pharmaceuticals, Inc.

Last Transcript: Supernus Pharmaceuticals, Inc.

Analysts' recommendations: Supernus Pharmaceuticals, Inc.

Press Releases: Supernus Pharmaceuticals, Inc.

News in other languages: Supernus Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Supernus Pharmaceuticals, Inc.

ETFs: Supernus Pharmaceuticals, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.	06-16	PR
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio	06-16	GL
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals	05-29	GL
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals	05-29	AQ
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference	05-28	GL

USA-Les valeurs à suivre à Wall Street (actualisé)	02-19
"Les actions US sont trop chères, mais on s'en fout"	02-19
En direct des marchés : Sanofi vend Opella, Stellantis revient au diesel, Intel à la découpe	02-19
Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)	21-10-18
Newron erhält fünfte Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)	21-10-18

1 day	-2.06%
1 week	+0.78%
Current month	+1.83%
1 month	+0.75%
3 months	+0.40%
6 months	-8.89%
Current year	-10.73%

1 week	31.56	33.3
1 month	31.32	33.7
Current year	29.16	40.28
1 year	25.55	40.28
3 years	21.99	42.09
5 years	17.2	42.09
10 years	9.51	61.25

Manager	Title	Age	Since
Jack Khattar CEO	Chief Executive Officer	63	2005-12-21
Timothy Dec DFI	Director of Finance/CFO	66	2021-08-22
Kevin T. Anderson CMP	Compliance Officer	62	2011-12-31

Director	Title	Age	Since
Jack Khattar BRD	Director/Board Member	63	2005-12-21
Charles Newhall CHM	Chairman	79	2016-08-09
Frederick Hudson BRD	Director/Board Member	79	2010-11-15

Name	Weight	AuM	1st Jan change
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	0.94%	29 M€	-6.60%	-
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	0.38%	23 M€	-8.96%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SUPERNUS PHARMACEUTICALS, INC.	-2.06%	+0.78%	+19.38%	+16.28%	2.02B
MERCK KGAA	+1.24%	-3.92%	-33.85%	-29.81%	55.29B
KYOWA KIRIN CO., LTD.	-0.22%	-0.90%	-8.34%	-18.23%	8.91B
HALOZYME THERAPEUTICS, INC.	-0.64%	-2.17%	+2.44%	+15.05%	6.51B
YUHAN CORPORATION	+3.07%	-2.16%	+34.28%	+108.87%	5.65B
SK BIOPHARMACEUTICALS CO., LTD.	+2.99%	+2.88%	+22.24%	+32.52%	5.31B
BETTA PHARMACEUTICALS CO., LTD.	-1.24%	-13.37%	+53.28%	-2.12%	3.22B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-0.10%	-3.42%	-1.97%	+13.57%	1.95B
INDIVIOR PLC	+1.95%	+2.15%	-20.38%	-28.29%	1.76B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.95%	-2.04%	-58.85%	-13.04%	1.72B
Average	+0.39%	-2.23%	+0.82%	+9.48%	9.23B
Weighted average by Cap.	+0.95%	-3.05%	-16.77%	-10.23%

	2025 *	2026 *
Net sales	625M 542M 511M 464M 859M 54.14B 967M 6.05B 2.31B 24.8B 2.35B 2.3B 91.18B	680M 590M 556M 505M 934M 58.9B 1.05B 6.58B 2.52B 26.98B 2.55B 2.5B 99.2B
Net income	-4.83M -4.19M -3.95M -3.59M -6.64M -419M -7.48M -46.77M -17.9M -192M -18.14M -17.75M -705M	17.14M 14.86M 14M 12.72M 23.54M 1.48B 26.52M 166M 63.45M 680M 64.3M 62.93M 2.5B
Net Debt	-	-